TY - JOUR
T1 - Poly (caprolactone)/sodium-alginate-functionalized halloysite clay nanotube nanocomposites
T2 - Potent biocompatible materials for wound healing applications
AU - Kouser, Sabia
AU - Prabhu, Ashwini
AU - Sheik, Sareen
AU - Prashantha, Kalappa
AU - Nagaraja, G. K.
AU - D'souza, Josline Neetha
AU - Navada, K. Meghana
AU - Manasa, D. J.
N1 - Funding Information:
The authors would like to thank the DST-PURSE, Mangalore University for providing instrumentation facilities, as well as the VGST (Vision Group of Science and Technology) by the Government of Karnataka for their support in this research work. One of the authors Sabia Kouser is grateful for the fellowship provided by the Directorate of Minorities. The authors thank Dr. Saraswathi P. Masti, Department of Chemistry, Karnataka Science College, Dharwad (DST-SERB, Project No. SB/EMEQ-213/2014) for providing mechanical testing facilities.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/9/25
Y1 - 2021/9/25
N2 - In this study, halloysite nanotubes (HNTs) were subjected to surface functionalization using sodium alginate and incorporated into poly(caprolactone) (PCL) to fabricate nanocomposites for potential wound healing applications. The nanocomposite films were fabricated through the solution casting technique and characterized using various instrumental methods. The films exhibited enhanced thermal and mechanical properties. FE-SEM and AFM analyses confirmed the uniform dispersion of the HNTs and increased roughness of the films, respectively. The swelling properties, in-vitro enzymatic degradation, and anti-inflammatory activity of the films were also analyzed. The MTT assay performed using NIH3T3 cell lines revealed enhanced cell proliferation (126 ± 1.38) of 5 wt% film. Besides, the cell adhesion tests of the films revealed their cytocompatibility. The scratch assay tests conducted for observing the effectiveness of the films for wound closure showed that the 5 wt% film offered a higher rate of fibroblast cell migration (32.24 ± 0.49) than the pristine PCL film. The HRBCMS assay demonstrated the hemocompatibility of these films. The biological test results indicated the delayed enzymatic degradability and haemocompatiblity of nanocomposites with enhanced cell adhesion, cell proliferation, and cell migration capabilities with respect to fibroblast cells. In summary, the synthesized nanocomposite films can be effectively used in wound healing applications after further clinical trials.
AB - In this study, halloysite nanotubes (HNTs) were subjected to surface functionalization using sodium alginate and incorporated into poly(caprolactone) (PCL) to fabricate nanocomposites for potential wound healing applications. The nanocomposite films were fabricated through the solution casting technique and characterized using various instrumental methods. The films exhibited enhanced thermal and mechanical properties. FE-SEM and AFM analyses confirmed the uniform dispersion of the HNTs and increased roughness of the films, respectively. The swelling properties, in-vitro enzymatic degradation, and anti-inflammatory activity of the films were also analyzed. The MTT assay performed using NIH3T3 cell lines revealed enhanced cell proliferation (126 ± 1.38) of 5 wt% film. Besides, the cell adhesion tests of the films revealed their cytocompatibility. The scratch assay tests conducted for observing the effectiveness of the films for wound closure showed that the 5 wt% film offered a higher rate of fibroblast cell migration (32.24 ± 0.49) than the pristine PCL film. The HRBCMS assay demonstrated the hemocompatibility of these films. The biological test results indicated the delayed enzymatic degradability and haemocompatiblity of nanocomposites with enhanced cell adhesion, cell proliferation, and cell migration capabilities with respect to fibroblast cells. In summary, the synthesized nanocomposite films can be effectively used in wound healing applications after further clinical trials.
UR - https://www.scopus.com/pages/publications/85113924506
UR - https://www.scopus.com/inward/citedby.url?scp=85113924506&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2021.121048
DO - 10.1016/j.ijpharm.2021.121048
M3 - Article
C2 - 34454027
AN - SCOPUS:85113924506
SN - 0378-5173
VL - 607
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 121048
ER -